HK1206355A1 - Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one [12-a]-1-[14][12-a]-1- - Google Patents

Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one [12-a]-1-[14][12-a]-1-

Info

Publication number
HK1206355A1
HK1206355A1 HK15107077.4A HK15107077A HK1206355A1 HK 1206355 A1 HK1206355 A1 HK 1206355A1 HK 15107077 A HK15107077 A HK 15107077A HK 1206355 A1 HK1206355 A1 HK 1206355A1
Authority
HK
Hong Kong
Prior art keywords
indol
diazepino
piperazino
ones
Prior art date
Application number
HK15107077.4A
Other languages
English (en)
Chinese (zh)
Inventor
西蒙娜．
．切卡雷利
拉維．姚高希亞
勒特 羅蘭．雅各布-
於爾根．維希曼
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1206355A1 publication Critical patent/HK1206355A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
HK15107077.4A 2012-08-06 2015-07-24 Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one [12-a]-1-[14][12-a]-1- HK1206355A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12179381 2012-08-06
PCT/EP2013/066344 WO2014023674A1 (en) 2012-08-06 2013-08-05 Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one

Publications (1)

Publication Number Publication Date
HK1206355A1 true HK1206355A1 (en) 2016-01-08

Family

ID=48918402

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107077.4A HK1206355A1 (en) 2012-08-06 2015-07-24 Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one [12-a]-1-[14][12-a]-1-

Country Status (25)

Country Link
US (1) US9284321B2 (es)
EP (1) EP2880036B1 (es)
JP (1) JP5974177B2 (es)
KR (1) KR101716062B1 (es)
CN (1) CN104540829B (es)
AR (1) AR092041A1 (es)
AU (1) AU2013301577B2 (es)
BR (1) BR112015000313A2 (es)
CA (1) CA2880682A1 (es)
CL (1) CL2015000143A1 (es)
CO (1) CO7141435A2 (es)
CR (1) CR20140545A (es)
EA (1) EA025884B1 (es)
HK (1) HK1206355A1 (es)
IL (1) IL236808B (es)
MA (1) MA37791B1 (es)
MX (1) MX362184B (es)
MY (1) MY185216A (es)
NZ (1) NZ703192A (es)
PE (1) PE20150341A1 (es)
PH (1) PH12015500059B1 (es)
SG (1) SG11201408529VA (es)
TW (1) TWI506027B (es)
UA (1) UA113013C2 (es)
WO (1) WO2014023674A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201506420WA (en) * 2013-02-18 2015-09-29 Theranos Inc Image analysis and measurement of biological samples
KR101767329B1 (ko) * 2013-04-02 2017-08-10 에프. 호프만-라 로슈 아게 피페라지노[1,2-a]인돌-1-온 및 [1,4]다이아제피노[1,2-a]인돌-1-온
CA2917628A1 (en) * 2013-09-12 2015-03-19 F. Hoffmann-La Roche Ag Indol-carboxamide derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1965981C3 (de) * 1968-02-13 1978-08-31 Sumitomo Chemical Co., Ltd., Osaka (Japan) 9-Phenyl-lO-oxopiperazino [l,2-a]-indole und Verfahren zu ihrer Herstellung
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
AU2006324089A1 (en) * 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
WO2008046072A2 (en) 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis
MX2009004898A (es) * 2006-11-09 2009-05-19 Hoffmann La Roche Derivados de indol y de benzofurano-2-carboxamida.
BR112013000414A2 (pt) 2010-07-07 2016-05-17 Univ Texas compostos proneurogênicos
KR101767329B1 (ko) * 2013-04-02 2017-08-10 에프. 호프만-라 로슈 아게 피페라지노[1,2-a]인돌-1-온 및 [1,4]다이아제피노[1,2-a]인돌-1-온

Also Published As

Publication number Publication date
EP2880036A1 (en) 2015-06-10
CR20140545A (es) 2015-01-12
KR101716062B1 (ko) 2017-03-13
MY185216A (en) 2021-04-30
AR092041A1 (es) 2015-03-18
UA113013C2 (uk) 2016-11-25
PH12015500059A1 (en) 2015-03-02
MA37791A1 (fr) 2016-05-31
KR20150027832A (ko) 2015-03-12
CO7141435A2 (es) 2014-12-12
TW201410679A (zh) 2014-03-16
CA2880682A1 (en) 2014-02-13
MA37791B1 (fr) 2016-12-30
JP2015524456A (ja) 2015-08-24
MX2015001318A (es) 2015-04-17
MX362184B (es) 2019-01-08
SG11201408529VA (en) 2015-01-29
AU2013301577A1 (en) 2014-12-18
EA025884B1 (ru) 2017-02-28
JP5974177B2 (ja) 2016-08-23
CN104540829B (zh) 2017-04-26
CN104540829A (zh) 2015-04-22
PE20150341A1 (es) 2015-02-28
EP2880036B1 (en) 2017-03-08
IL236808B (en) 2018-05-31
PH12015500059B1 (en) 2015-03-02
BR112015000313A2 (pt) 2017-06-27
WO2014023674A1 (en) 2014-02-13
US9284321B2 (en) 2016-03-15
NZ703192A (en) 2016-04-29
AU2013301577B2 (en) 2017-03-30
US20150246922A1 (en) 2015-09-03
TWI506027B (zh) 2015-11-01
CL2015000143A1 (es) 2015-06-19
EA201590125A1 (ru) 2015-05-29

Similar Documents

Publication Publication Date Title
HK1216174A1 (zh) 氨基取代的咪唑並 吡啶羧酰胺和它們的用途
ZA201906379B (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
HK1203407A1 (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof [12-b]
HK1221469A1 (zh) -芳基-取代的咪唑並 吡啶及其用途
HK1185881A1 (zh) 取代的咪唑並 噠嗪
IL233808B (en) History of triazole[5,4-d]pyrimidine and drugs containing them
HK1220201A1 (zh) 作爲成像工具的咪唑並 吡啶- -胺類
HK1206355A1 (en) Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one [12-a]-1-[14][12-a]-1-
HK1221457A1 (zh) 種吡嗪並 吲哚化合物及其製備方法和在藥物中的應用
HK1213553A1 (zh) 呱嗪並 吲哚- -酮和 二氮雜*並 吲哚- -酮
HK1205504A1 (en) Substituted pyrazolo[1,5-a]pyridines, their preparation and use as medicaments [1,5-a]
HK1221458A1 (zh) 種吡嗪並 吲哚化合物及其製備方法和在藥物中的應用
IL229181A (en) Antifungals 5, 6 - Dihydro - 4h - Pyrolo [1, 2a - [4,1] benzo - diazepines and 6h - Pyrolo [2,1 - a] benzodiazepines preserved with heterocyclic history